{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:09:29Z","timestamp":1753182569388},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.mehy.2019.109376","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T11:39:10Z","timestamp":1566214750000},"page":"109376","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adjunctive bradyzoite-directed therapy for reducing complications of congenital toxoplasmosis"],"prefix":"10.1016","volume":"133","author":[{"given":"Samuel D.","family":"Chorlton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109376_b0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2471\/BLT.12.111732","article-title":"The global burden of congenital toxoplasmosis: a systematic review","volume":"91","author":"Torgerson","year":"2013","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.mehy.2019.109376_b0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3860","article-title":"Diseases C on I. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States","volume":"139","author":"Maldonado","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.mehy.2019.109376_b0015","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1542\/peds.2013-2153","article-title":"Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence","volume":"133","author":"Wallon","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.mehy.2019.109376_b0020","doi-asserted-by":"crossref","first-page":"552.e1","DOI":"10.1016\/j.ajog.2010.06.002","article-title":"Long-term outcome of children with congenital toxoplasmosis","volume":"203","author":"Berr\u00e9bi","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.mehy.2019.109376_b0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199604113341517","article-title":"Long-term follow-up of patients with congenital ocular toxoplasmosis","volume":"334","author":"Peyron","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2019.109376_b0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bmj.321.7254.142","article-title":"Sources of toxoplasma infection in pregnant women: European multicentre case-control study","volume":"321","author":"Cook","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2019.109376_b0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0140-6736(07)60072-5","article-title":"Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients\u2019 data","volume":"369","author":"SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group","year":"2007","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.mehy.2019.109376_b0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CMR.11.2.267","article-title":"Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts","volume":"11","author":"Dubey","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mehy.2019.109376_b0045","first-page":"11","article-title":"Neurologic and developmental outcome in treated congenital toxoplasmosis","volume":"95","author":"Roizen","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.mehy.2019.109376_b0050","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/501360","article-title":"Outcome of treatment for congenital toxoplasmosis, 1981\u20132004: the national collaborative chicago-based, congenital toxoplasmosis study","volume":"42","author":"McLeod","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2019.109376_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0147-9571(02)00058-9","article-title":"Pathogenesis of toxoplasmosis","volume":"26","author":"Bhopale","year":"2003","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.mehy.2019.109376_b0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-4758(98)01377-5","article-title":"Pathogenesis of toxoplasmic retinochoroiditis","volume":"15","author":"Roberts","year":"1999","journal-title":"Parasitol Today"},{"key":"10.1016\/j.mehy.2019.109376_b0065","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.placenta.2009.08.002","article-title":"Azithromycin Inhibits Vertical Transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae)","volume":"30","author":"Costa","year":"2009","journal-title":"Placenta"},{"key":"10.1016\/j.mehy.2019.109376_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molbiopara.2006.03.010","article-title":"Histone mediated gene activation in Toxoplasma gondii","volume":"148","author":"Sullivan","year":"2006","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.mehy.2019.109376_b0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1348-0421.2004.tb03504.x","article-title":"Evaluation of the effects of sulfamethoxazole on Toxoplasma gondii loads and stage conversion in IFN-\u03b3 knockout mice using QC-PCR","volume":"48","author":"Belal","year":"2004","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.mehy.2019.109376_b0080","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1099\/0022-1317-51-10-879","article-title":"The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS","volume":"51","author":"Contini","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.mehy.2019.109376_b0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/mcpr.2001.0394","article-title":"Efficacy of a novel reverse transcriptase-polymerase chain reaction (RT-PCR) for detecting Toxoplasma gondii bradyzoite gene expression in human clinical specimens","volume":"16","author":"Cultrera","year":"2002","journal-title":"Mol Cell Probes"},{"key":"10.1016\/j.mehy.2019.109376_b0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.exppara.2010.04.003","article-title":"Recrudescence of Toxoplasma gondii infection in chronically infected rats (Rattus norvegicus)","volume":"125","author":"da Silva","year":"2010","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.mehy.2019.109376_b0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.exppara.2008.02.007","article-title":"Toxoplasma gondii: Protection against colonization of the brain and muscles in a rat model","volume":"119","author":"Freyre","year":"2008","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.mehy.2019.109376_b0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.exppara.2008.06.007","article-title":"Toxoplasma gondii: an improved rat model of congenital infection","volume":"120","author":"Freyre","year":"2008","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.mehy.2019.109376_b0105","first-page":"99","article-title":"Murine model of drug-induced reactivation of Toxoplasma gondii","volume":"40","author":"Djurkovic Djakovic","year":"2001","journal-title":"Acta Protozool"},{"key":"10.1016\/j.mehy.2019.109376_b0110","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically available medicines demonstrating anti-toxoplasma activity","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0115","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00436-018-6027-z","article-title":"Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review","volume":"117","author":"Montazeri","year":"2018","journal-title":"Parasitol Res"},{"key":"10.1016\/j.mehy.2019.109376_b0120","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.05183-11","article-title":"Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis","volume":"56","author":"Chew","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0125","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1128\/AAC.41.7.1531","article-title":"Effects of 2\u2019,3\u2019-dideoxyinosine on Toxoplasma gondii cysts in mice","volume":"41","author":"Sarciron","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exppara.2015.06.005","article-title":"Could miltefosine be used as a therapy for toxoplasmosis?","volume":"157","author":"Eissa","year":"2015","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.mehy.2019.109376_b0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.exppara.2009.12.011","article-title":"Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model","volume":"124","author":"Martins-Duarte","year":"2010","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.mehy.2019.109376_b0140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.36.2.326","article-title":"In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii","volume":"36","author":"Araujo","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0145","first-page":"111","article-title":"An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii","volume":"75","author":"Ferguson","year":"1994","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.mehy.2019.109376_b0150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/infdis\/167.2.494","article-title":"The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine","volume":"167","author":"Araujo","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2019.109376_b0155","first-page":"1171","article-title":"Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease","volume":"39","author":"Gormley","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.mehy.2019.109376_b0160","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkf251","article-title":"Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii","volume":"50","author":"Djurkovi\u0107-Djakovi\u0107","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0165","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1128\/AAC.01683-15","article-title":"Guanabenz repurposed as an antiparasitic with activity against acute and latent Toxoplasmosis","volume":"59","author":"Benmerzouga","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1051\/parasite\/1998053223","article-title":"Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis","volume":"5","author":"Sordet","year":"1998","journal-title":"Parasite"},{"key":"10.1016\/j.mehy.2019.109376_b0175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.35.2.293","article-title":"Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii","volume":"35","author":"Araujo","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0169-4758(93)90040-M","article-title":"Atovaquone\u2014a novel broad-spectrum anti-infective drug","volume":"9","author":"Hudson","year":"1993","journal-title":"Parasitol Today"},{"key":"10.1016\/j.mehy.2019.109376_b0185","unstructured":"U.S. Food & Drug Administration. SUPPL-23: labeling-package insert for MALARONE; 2019."},{"key":"10.1016\/j.mehy.2019.109376_b0190","doi-asserted-by":"crossref","DOI":"10.4076\/1757-1626-2-8826","article-title":"Patient with toxoplasmosis and glucose-6-phosphate dehydrogenase deficiency: a case report","volume":"2","author":"Nunes","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.mehy.2019.109376_b0195","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/339551","article-title":"Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of Toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237\/ANRS 039 study","volume":"34","author":"Chirgwin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2019.109376_b0200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0140-6736(92)92172-C","article-title":"Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program","volume":"340","author":"Kovacs","year":"1992","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.mehy.2019.109376_b0205","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/clinids\/24.3.422","article-title":"Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS","volume":"24","author":"Torres","year":"1997","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.mehy.2019.109376_b0210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00417-010-1379-9","article-title":"Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?","volume":"248","author":"Winterhalter","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.mehy.2019.109376_b0215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0161-6420(99)90021-0","article-title":"Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients11The authors have no financial interest in atovaquone or Burroughs Wellcome Co","volume":"106","author":"Pearson","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mehy.2019.109376_b0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10792-007-9047-8","article-title":"Active ocular toxoplasmosis in Turkish patients: a report on 109 cases","volume":"26","author":"Tugal-Tutkun","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.mehy.2019.109376_b0225","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/bjo.2007.123661","article-title":"Recurrence characteristics in European patients with ocular toxoplasmosis","volume":"92","author":"Garweg","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.mehy.2019.109376_b0230","first-page":"1107","article-title":"Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group","volume":"10","author":"Katlama","year":"1996","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.mehy.2019.109376_b0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09273940600659740","article-title":"Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient","volume":"14","author":"Baatz","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.mehy.2019.109376_b0240","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.37.11.2371","article-title":"In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii","volume":"37","author":"Romand","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0245","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00347-007-1535-8","article-title":"Okul\u00e4re Toxoplasmose","volume":"104","author":"Pleyer","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mehy.2019.109376_b0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.3.4.573","article-title":"CNS pharmacokinetics of antifungal agents","volume":"3","author":"Kethireddy","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.mehy.2019.109376_b0255","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1086\/340825","article-title":"Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection","volume":"185","author":"Haynes","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mehy.2019.109376_b0260","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/AAC.44.6.1512-1517.2000","article-title":"Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis","volume":"44","author":"Sorensen","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2019.109376_b0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2019.109376_b0270","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/515110","article-title":"A Comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis","volume":"28","author":"Saag","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2019.109376_b0275","unstructured":"U.S. Food & Drug Administration. Miltefosine label; 2014."},{"key":"10.1016\/j.mehy.2019.109376_b0280","unstructured":"Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection: archived drugs; 2019."},{"key":"10.1016\/j.mehy.2019.109376_b0285","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijpara.2009.02.004","article-title":"Toxoplasmosis: a history of clinical observations","volume":"39","author":"Weiss","year":"2009","journal-title":"Int J Parasitol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719307881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719307881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T17:16:36Z","timestamp":1573578996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719307881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":57,"alternative-id":["S0306987719307881"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109376","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive bradyzoite-directed therapy for reducing complications of congenital toxoplasmosis","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109376"}}